Search results

Order by most recent / most popular / relevance

Results: 1-5 of 5

New circular on Chinese generic pharmaceutical manufacturers

CMS Cameron McKenna
-
China
-
March 21 2013

Non-Chinese companies seem to have new opportunities to acquire Chinese generic pharmaceutical manufacturers through transfer of technology thanks to

Teva Canada Limited v. Wyeth LLC, December 9, 2011, 2011 FC 1442, venlafaxine

Gowling Lafleur Henderson LLP
-
Canada
-
January 23 2012

This was a successful motion by the defendants to dismiss the plaintiff’s action for s.8 damages following a recent decision by Hughes J. (2011 FC 1169) in which he held that the plaintiff Teva was not permitted to continue ratiopharm’s claim for s. 8 damages following their merger

SFDA GMP work plan encourages M&A and technology transfer transactions involving local drug manufacturers

Sidley Austin LLP
-
Chile
-
January 20 2012

On January 6, the State Food and Drug Administration of China (SFDA) issued the Notice on Implementation of Drug GMP 2010 (the Notice

Teva Canada Limited v. Wyeth LLC et al, October 17, 2011, 2011 FC 1169, venlafaxine (motion for summary judgment)

Gowling Lafleur Henderson LLP
-
Canada
-
November 18 2011

In response to a motion brought by Teva for summary judgment of the issue of whether Teva can continue a s. 8 claim initially brought by ratiopharm, Justice Hughes found that this case met the criteria for being brought in a summary nature and proceeded to find that in the circumstances Teva could not pursue the s.8 action and dismissed the action

Pharma merger activity attributed to “patent cliff”

Shook Hardy & Bacon LLP
-
USA
-
November 18 2010

Noting that many of the pharmaceutical industry's best-selling products will soon lose their patent protection, industry analysts have reportedly suggested that the potential loss of nearly one-third of industry revenues in the near term could account for recent merger activity among the world's largest pharmaceutical companies

Search results

New circular on Chinese generic pharmaceutical manufacturers

Teva Canada Limited v. Wyeth LLC, December 9, 2011, 2011 FC 1442, venlafaxine

SFDA GMP work plan encourages M&A and technology transfer transactions involving local drug manufacturers

Teva Canada Limited v. Wyeth LLC et al, October 17, 2011, 2011 FC 1169, venlafaxine (motion for summary judgment)

Pharma merger activity attributed to “patent cliff”

Current Search

Suggested Facets

Author

Firm Name

Jurisdiction